The Effects of Rhus Coriaria L. on Serum Uric Acid Levels
Nøgleord
Abstrakt
Beskrivelse
Rhus coriaria L.(Rhus) is a well-known spice widely consumed in the world which has also been utilized extensively for medicinal purposes. The antioxidant components of this plant made it a favorable target for laboratory and animal studies in different conditions such as oxidative stress cytotoxicity, diabetes and hyperlipidemia. Rhus (Somagh) is found in temperate and tropical regions worldwide, often growing in areas of marginal agricultural capacity. Rhus is used as an herbal remedy in traditional medicine because of its assumed analgesic, antidiarrheic, antiseptic, anorexic and antihyperglycemic properties. The fruits of Rhus contain flavonols, phenolic acids, hydrolysable tannins, anthocyans and organic acids such as malice, citric and tartaric acids. Some studies have shown that polyphenols could have beneficial effects on cardiovascular disease and cancer and could be regarded as bioactive compounds with a high potential health-promoting capacity. Phenolic compounds inhibit lipid peroxidation, scavenge the superoxide anion and hydroxyl radical, and enhance the activities of detoxifying enzymes.
Uric acid (UA; 7,9-dihydro-1H-purine-2,6,8(3H)-trione) has been implicated as a risk factor and cause of numerous disease states. Some disease states, such as gout, hypertension, and cardiovascular disease, have been shown to result when UA levels in the blood are too high. Hyperuricemia predicts the development of hypertension in the general population, and an independent positive correlation between UA levels and the occurrence of hypertension has been reported. Hyperuricemia may also be a risk factor for cardiovascular disease, myocardial infarction, and stroke.
The manipulation of serum UA levels has become a popular strategy in the treatment of a variety of diseases. This is either accomplished through dietary and lifestyle changes or through treatment with UA reducing drugs.
The aim of this study is to evaluate the effects of Rhus coriaria L. (Rhus) commonly known as Somagh on serum uric acid levels.
Datoer
| Sidst bekræftet: | 03/31/2019 |
| Først indsendt: | 08/30/2016 |
| Anslået tilmelding indsendt: | 08/30/2016 |
| Først indsendt: | 09/06/2016 |
| Sidste opdatering indsendt: | 04/03/2019 |
| Sidste opdatering indsendt: | 04/07/2019 |
| Faktisk startdato for undersøgelsen: | 05/31/2019 |
| Anslået primær afslutningsdato: | 10/31/2019 |
| Anslået afslutningsdato for undersøgelsen: | 11/30/2019 |
Tilstand eller sygdom
Intervention / behandling
Drug: Rhus (Somagh)
Drug: Placebo
Fase
Armgrupper
| Arm | Intervention / behandling |
|---|---|
| Active Comparator: Rhus (Somagh) 500 mg twice daily after meal for 6 weeks | Drug: Rhus (Somagh) 500 mg twice daily after meal for 6 weeks |
| Placebo Comparator: Placebo 500 mg twice daily after meal for 6 weeks | Drug: Placebo 500 mg twice daily after meal for 6 weeks |
Kriterier for støtteberettigelse
| Alder berettiget til undersøgelse | 20 Years Til 20 Years |
| Køn, der er berettiget til undersøgelse | All |
| Accepterer sunde frivillige | Ja |
| Kriterier | Inclusion Criteria: - Healthy individuals Exclusion Criteria: - Serum uric acid levels that need medical treatment - Gout - Diabetes mellitus - Hypo. or hyperthyroidism - Any systemic illnesses e.g. liver cirrhosis, acute or chronic renal failure, heart failure - Use of drugs: Uric acid lowering agents - Pregnancy - Lactation - History of allergic reaction to Somagh |
Resultat
Primære resultatforanstaltninger
1. serum uric acid levels [6 weeks]
Sekundære resultatforanstaltninger
1. Number of patients with adverse events. [6 weeks]
